Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Dynavax Technologies Corporation
Dynavax Technologies Corp is a clinical-stage biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor ("TLR") stimulation.
IPO Date: February 19, 2004
Sector: Healthcare
Industry: Biotech
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.22 | 3.03%
Avg Daily Range (30 D): $0.28 | 2.38%
Avg Daily Range (90 D): $0.20 | 1.60%
Institutional Daily Volume
Avg Daily Volume: 1.36M
Avg Daily Volume (30 D): 2.31M
Avg Daily Volume (90 D): 1.88M
Trade Size
Avg Trade Size (Sh.): 189
Avg Trade Size (Sh.) (30 D): 93
Avg Trade Size (Sh.) (90 D): 96
Institutional Trades
Total Inst.Trades: 4,356
Avg Inst. Trade: $2.38M
Avg Inst. Trade (30 D): $2.4M
Avg Inst. Trade (90 D): $2.93M
Avg Inst. Trade Volume: .19M
Avg Inst. Trades (Per Day): 2
Market Closing Trades
Avg Closing Trade: $2.96M
Avg Closing Trade (30 D): $3.72M
Avg Closing Trade (90 D): $3.86M
Avg Closing Volume: 248.33K
       
News
Sep 2, 2024 @ 8:15 PM
Liver Fibrosis Market Is Expected to Reach USD 43....
Source: The Brainy Insights
Aug 23, 2024 @ 2:00 PM
Cancer Vaccines Market Size Expected to Reach USD ...
Source: Towards Healthcare
May 9, 2024 @ 6:15 AM
Dynavax Technologies (DVAX) Q1 2024 Earnings Call ...
Source: newsfeedback@fool.com (Motley Fool Transcribing)
May 8, 2024 @ 9:20 PM
Dynavax Technologies (DVAX) Reports Q1 Loss, Misse...
Source: Zacks Equity Research
May 7, 2024 @ 9:50 PM
Myriad Genetics (MYGN) Reports Q1 Loss, Tops Reven...
Source: Zacks Equity Research
Financials
  TTM Q1 2025 Q4 2024
Basic EPS $-.49 $-.77 $.06
Diluted EPS $-.52 $-.77 $.05
Revenue $ 294.62M $ 68.16M $ 72.03M
Gross Profit $ $ $
Net Income / Loss $ -60.07M $ -96.1M $ 7.05M
Operating Income / Loss $ -9.98M $ -23.63M $ -1.63M
Cost of Revenue $ $ $
Net Cash Flow $ -80.3M $ -44.15M $ -23.46M
PE Ratio    
Splits
Nov 10, 2014:   10:1